- Secukinumab 150mg belongs to monoclonal antibody which is a protein which recognises and connect to an inflammatory protein called Interleukin 17A (IL-17A). In patients with psoriatic arthritis and ankylosing spondylitis, the body’s immune system produces an increased amount of IL-17A which causes the symptoms such as swollen and painful joint.
- Scapho 150mg is a prescription drugs which is used under proper guidance of medical oncologist
INDICATION
- Scapho 150mg indicated for the treatment of following condition
- Plaque Psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis.
DOSAGE
Plaque Psoriasis:
- Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
- initially at week 8, administer 300 mg SC once monthly
- For some patients may be acceptable containing dose of 150 mg
Psoriatic Arthritis : Indicated for adults with active psoriatic arthritis
Recommended dosage
- Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
- Scapho 150mg with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
- Scapho 150mg without loading dose administrated 150 mg SC q4wk.
- Consider a dosage of 300 mg, if a patient continues to have active psoriatic arthritis
- May be administered with or without methotrexate.
Ankylosing Spondylitis:
- Given with or without a loading dosage by SC injection
- Scapho 150mg with loading dose is administrated 150mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
- Scapho 150mg without a loading dose is administrated 150mg SC q4wk
MECHANISM
- Secukinumab 150mg mechanism as Interleukin-17A (IL-17A) is a cornerstone cytokine (messenger protein) contains in the development of psoriasis and is found in peak concentrations in psoriasis plaques.
- Secukinumab 150mg consist of human IgG1 monoclonal antibody which selectively binds to IL-17A, rapidly prohibiting its pro-inflammatory effects.
ADME
- Maximum plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days
- Volume of distribution is 7.1 – 8.6 (IV administration)
- The drug scapho is Metabolized via intracellular catabolism.
- Scapho 150mg has half-life is 22-31 days
PRECAUTION
- Scapho 150mg may have high risk of infections; use with caution in patients with chronic infection or a history of recurrent infection
- Before to initiation of scapho,start with anti-TB therapy in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed
- May infuriate Crohn disease
- Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho immediately and start anaphylaxis treatment
DRUG INTERACTION
- Live vaccinations combination with scapho should be avoided
- CYP450 substrates concomitant use with scapho injection may altered by increased levels of certain cytokines.
CONTRAINDICATION
- Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients
STORAGE
- Store the drug at 2℃ to 8℃.
MISSED DOSE
- In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them, thereby missed dose should be avoid and follow the regular dosing schedule.
SIDE EFFECTS
- Infections
- Nasopharyngitis
- Diarrhea
- URT infection
- Rhinitis
- Oral herpes
- Pharyngitis
- Urticaria
- Rhinorrhoea
CONTACT DETAILS
Phone : 9987711567
Email : applepharmaceutical@gmail.com
Email : info@myapplepharma.com
katherine 